BioSig Technologies (BSGM), a medical-technology company fresh off a merger with tokenization firm Streamex, said it signed definitive agreements for up to $1.1 billion in financing to fund a gold-backed treasury model and scale its tokenization platform for real-world assets (RWAs) like gold and other commodities.

The capital raise includes $100 million in senior secured convertible debentures and a $1 billion equity line of credit. The debentures accrue 4% interest and are convertible into common shares, giving holders the rights to a sizable equity position. Under the equity line of credit, the firm may issue new shares and sell up to $1 billion of common stock to investors for up 36 months.